These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 17333089)

  • 1. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C; Reinert RR; von der Schulenburg JM
    Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
    Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ; Fletcher MA; Fritzell B; Ciuryla V; Schranz J
    Vaccine; 2007 Mar; 25(13):2420-7. PubMed ID: 17049677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
    Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
    Giglio ND; Cane AD; Micone P; Gentile A
    Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Costs of pneumococcal infections and cost evaluation of heptavalent conjugate vaccine].
    D'Alessandro D
    Ann Ig; 2002; 14(6 Suppl 7):43-8. PubMed ID: 12638364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.